Terms: = Bone cancer AND REL, I-Rel, 5966, ENSG00000162924, C-Rel
39 results:
1. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract] [Full Text] [Related]
2. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation.
Spyridonidis A; Labopin M; Gedde-Dahl T; Ganser A; Stelljes M; Craddock C; Wagner-Drouet EM; Versluis J; Schroeder T; Blau IW; Wulf GG; Dreger P; Olesen G; Sengeloev H; Kröger N; Potter V; Forcade E; Passweg J; de Latour RP; Maertens J; Wilson KMO; Bourhis JH; Finke J; Brissot E; Bazarbachi A; Giebel S; Savani BP; Nagler A; Ciceri F; Mohty M
Bone Marrow Transplant; 2024 Feb; 59(2):217-223. PubMed ID: 37978322
[TBL] [Abstract] [Full Text] [Related]
3. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
[TBL] [Abstract] [Full Text] [Related]
4. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M
Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837
[TBL] [Abstract] [Full Text] [Related]
5. Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis.
Nagler A; Ngoya M; Galimard JE; Labopin M; Bornhäuser M; Stelljes M; Finke J; Ganser A; Einsele H; Kröger N; Brecht A; Bethge W; Edinger M; Kulagin A; Passweg J; Blau IW; Elmaagacli A; Schäfer-Eckart K; Platzbecker U; Schroeder T; Bunjes D; Tischer J; Martin S; Spyridonidis A; Giebel S; Savani B; Mohty M
Clin Cancer Res; 2022 Oct; 28(19):4258-4266. PubMed ID: 35670780
[TBL] [Abstract] [Full Text] [Related]
6. IKKα-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines.
Song NY; Li X; Ma B; Willette-Brown J; Zhu F; Jiang C; Su L; Shetty J; Zhao Y; Shi G; Banerjee S; Wu X; Tran B; Nussinov R; Karin M; Hu Y
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35121655
[TBL] [Abstract] [Full Text] [Related]
7. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Pasvolsky O; Yeshurun M; Fraser R; Estrada-Merly N; Rozovski U; Shargian-Alon L; Assal A; Banerjee R; Bumma N; Gale RP; Hagen P; Holmberg L; Hossain NM; Lazarus HM; Lee C; Mian H; Miller KC; Nathan S; Nagler A; Nishihori T; Parrondo RD; Patel S; Schroeder MA; Usmani SZ; Wang T; Wirk B; Kumar S; Shah N; Qazilbash MH; D'Souza A
Bone Marrow Transplant; 2022 Jan; 57(1):31-37. PubMed ID: 34608275
[TBL] [Abstract] [Full Text] [Related]
8. The Anatomical relationships in the Space of Retzius for Penile Implants: An MRI Analysis.
Punjani N; Monteiro L; Sullivan JF; Flores J; Ortega Y; Matsushita K; Choi JM; Elterman D; Akin O; Nelson CJ; Sandhu JS; Mulhall JP
J Sex Med; 2021 Nov; 18(11):1830-1834. PubMed ID: 34548263
[TBL] [Abstract] [Full Text] [Related]
9. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract] [Full Text] [Related]
10. The ubiquitin ligase Peli1 inhibits ICOS and thereby Tfh-mediated immunity.
Huang X; Hao S; Liu J; Huang Y; Liu M; Xiao C; Wang Y; Pei S; Yu T; Xu J; Wang H; Dai D; Su X; Xiao Y
Cell Mol Immunol; 2021 Apr; 18(4):969-978. PubMed ID: 33707688
[TBL] [Abstract] [Full Text] [Related]
11. Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (rel).
Borlenghi E; Pagani C; Zappasodi P; Bernardi M; Basilico C; Cairoli R; Fracchiolla N; Todisco E; Turrini M; Cattaneo C; Da Vià M; Ciceri F; Passamonti F; Mancini V; Sciumè M; Cerqui E; Sciumè M; Rossi G
J Geriatr Oncol; 2021 May; 12(4):550-556. PubMed ID: 33097455
[TBL] [Abstract] [Full Text] [Related]
12. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Munshi PN; Vesole D; Jurczyszyn A; Zaucha JM; St Martin A; Davila O; Agrawal V; Badawy SM; Battiwalla M; Chhabra S; Copelan E; Kharfan-Dabaja MA; Farhadfar N; Ganguly S; Hashmi S; Krem MM; Lazarus HM; Malek E; Meehan K; Murthy HS; Nishihori T; Olin RL; Olsson RF; Schriber J; Seo S; Shah G; Solh M; Tay J; Kumar S; Qazilbash MH; Shah N; Hari PN; D'Souza A
Cancer; 2020 Dec; 126(23):5077-5087. PubMed ID: 32965680
[TBL] [Abstract] [Full Text] [Related]
13. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT).
Poiani M; Labopin M; Battipaglia G; Beelen DW; Tischer J; Finke J; Brecht A; Forcade E; Ganser A; Passweg JR; Labussiere-Wallet H; Yakoub-Agha I; Schäfer-Eckart K; Kroeger N; Guffroy B; Ruggeri A; Esteve J; Nagler A; Mohty M
Am J Hematol; 2021 Jan; 96(1):40-50. PubMed ID: 32944990
[TBL] [Abstract] [Full Text] [Related]
14. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.
Spyridonidis A; Labopin M; Savani BN; Niittyvuopio R; Blaise D; Craddock C; Socié G; Platzbecker U; Beelen D; Milpied N; Cornelissen JJ; Ganser A; Huynh A; Griskevicius L; Giebel S; Aljurf M; Brissot E; Malard F; Esteve J; Peric Z; Baron F; Ruggeri A; Schmid C; Gilleece M; Gorin NC; Lanza F; Shouval R; Versluis J; Bug G; Fløisand Y; Ciceri F; Sanz J; Bazarbachi A; Nagler A; Mohty M
Bone Marrow Transplant; 2020 Jun; 55(6):1114-1125. PubMed ID: 31996792
[TBL] [Abstract] [Full Text] [Related]
15. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
Dieckmeyer M; Ruschke S; Rohrmeier A; Syväri J; Einspieler I; Seifert-Klauss V; Schmidmayr M; Metz S; Kirschke JS; Rummeny EJ; Zimmer C; Karampinos DC; Baum T
BMC Musculoskelet Disord; 2019 Nov; 20(1):515. PubMed ID: 31694630
[TBL] [Abstract] [Full Text] [Related]
16. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.
Herrera AF; Chen L; Khajavian S; Chase M; Darrah J; Maloney D; Ho VT; Soiffer RJ; Antin JH; Forman SJ; Nademanee AP; Chen YB; Armand P; Shadman M
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2383-2387. PubMed ID: 31394277
[TBL] [Abstract] [Full Text] [Related]
17. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (rel) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract] [Full Text] [Related]
18. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Sauter CS; Senechal B; Rivière I; Ni A; Bernal Y; Wang X; Purdon T; Hall M; Singh AN; Szenes VZ; Yoo S; Dogan A; Wang Y; Moskowitz CH; Giralt S; Matasar MJ; Perales MA; Curran KJ; Park J; Sadelain M; Brentjens RJ
Blood; 2019 Aug; 134(7):626-635. PubMed ID: 31262783
[TBL] [Abstract] [Full Text] [Related]
19. Activation of TNF-α/NF-κB axis enhances CRL4B
Zhang C; Chen B; Jiang K; Lao L; Shen H; Chen Z
Mol Oncol; 2018 Apr; 12(4):476-494. PubMed ID: 29377600
[TBL] [Abstract] [Full Text] [Related]
20. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.
Herrera AF; Rodig SJ; Song JY; Kim Y; Griffin GK; Yang D; Nikolaenko L; Mei M; Bedell V; Dal Cin P; Pak C; Alyea EP; Budde LE; Chen R; Chen YB; Chan WC; Cutler CS; Ho VT; Koreth J; Krishnan A; Murata-Collins JL; Nikiforow S; Palmer J; Pihan GA; Pillai R; Popplewell L; Rosen ST; Siddiqi T; Sohani AR; Zain J; Kwak LW; Weisenburger DD; Weinstock DM; Soiffer RJ; Antin JH; Forman SJ; Nademanee AP; Armand P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):514-520. PubMed ID: 29196080
[TBL] [Abstract] [Full Text] [Related]
[Next]
